Biotechnology is essential to the EU’s healthcare innovation, enabling advanced treatments and better outcomes for citizens. The BPI sees the EU Biotech Act as a key opportunity to accelerate this progress. For the EU to regain leadership in breakthrough therapies, it must rapidly translate scientific advances into accessible treatments through aligned legislative and non-legislative measures, such as the EU Competitiveness Compass, the Life Science Strategy, the EU Innovation Act, or FP10.
